Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count-Reference-Cited by-同舟云学术

Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count

Published:1998-03 Issue:1 Volume:24 Page:9-13
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Trapp Oliver M,Beykirch Maria K,Petrides Petro E

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference14 articles.

1. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival;Hehlmann;Leuk Lymph,1996

2. Anagrelide;Spencer;Drugs,1994

3. Anagrelide as a new platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications;Tefferi;Sem Thromb Hemost,1997

4. Anagrelide, a novel platelet lowering option in essential thrombocythemia: Treatment experience in 48 patients in Germany;Petrides;Eur J Hematol,1998

5. Thrombohemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function;Barbui;Eur J Cancer Clin Oncol,1983

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib;Cell Biochemistry and Function;2021-02-10

2. Bleeding and Thrombosis in Hematologic Neoplasia;Neoplastic Diseases of the Blood;2017-09-23

3. Solid-Phase Synthesis of Anagrelide Sulfonyl Analogues;ACS Combinatorial Science;2014-04-23

4. Anagrelide hydrochloride for essential thrombocythemia;Expert Opinion on Orphan Drugs;2013-11-09

5. Bleeding and Thrombosis in Hematologic Neoplasia;Neoplastic Diseases of the Blood;2012-07-27